Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’ [PDF]
, 2018 Gerald F. Watts, Richard Norman
openalex +1 more source
Anti-PCSK9 Treatment Attenuates Liver Fibrosis via Inhibiting Hypoxia-Induced Autophagy in Hepatocytes [PDF]
, 2023 Liuxin Ning +6 more
openalex +1 more source
The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research. [PDF]
, 2013 Elguindy, A, Yacoub, MH
core +1 more source
Experiencia del paciente en tratamiento con inhibidores de pcsk9 con el modelo de atención farmacéutica cmo [PDF]
, 2019 La Atención Farmacéutica clásica se basa en la identificación, resolución y prevención de los PRM, excluyendo como factor principal los problemas asociados al paciente.
Garcés Troncoso, Vanessa
core
Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
, 2022 Shakir Ahamad, Shahnawaz Ali Bhat
openalex +1 more source
Frontiers in MedicineBackground and aimsProprotein convertase subtilisin/kexin type 9 (PCSK9) increases circulating LDL levels and cardiovascular disease (CVD) risk; its levels may be related to the dysregulation of glycemic control and may be affected by estrogens.
Michelangelo Rottura +12 more
doaj +1 more source
Análisis de las controversias en los niveles de colesterol-LDL como indicador de riesgo cardiovascular [PDF]
, 2018 [ES] Objetivo: analizar las controversias existentes entre las guías de práctica clínica actuales y esclarecer qué recomendaciones pueden estar mejor fundamentadas en evidencia sólida y cuales pueden tener evidencia más débil.
Zubiaur Zamacola, Jon
core
Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained [PDF]
, 2018 Paul Lebeau +11 more
openalex +1 more source
New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects [PDF]
, 2021 Qidi Ying, Dick C. Chan, Gerald F. Watts
openalex +1 more source
Revisiting Outcomes–Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab
, 2017 Inmaculada Hernandez
openalex +2 more sources